Brief: Algorae Pharmaceuticals Provides NTCELL Project Update
14/02/2024 10:27
Feb 14 (Reuters) - Algorae Pharmaceuticals Ltd 1AI.AX :
* NTCELL PROJECT UPDATE
* CONTINUES ITS SCIENTIFIC REVIEW OF NTCELL DEVELOPMENT
PROGRAM
* RESOLVED TO TERMINATE ITS AGREEMENT WITH NZENO LTD WITH
IMMEDIATE EFFECT
* INVESTIGATING UTILITY OF THERAPEUTIC APPROACH THAT
COMBINES DEEP
BRAIN STIMULATION AND NTCELL IMPLANTED THERAPY
* CO AND NZENO RESOLVED TO ENTER NEW DISCUSSIONS FOR
PROVISION OF
CHOROID PLEXUS TISSUE IN FUTURE
Source text for Eikon: ID:nASX8LjlnC
Further company coverage: 1AI.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Algorae Pharmaceuticals
See all newsBrief: Algorae Pharmaceuticals Executes License & Supply Agreement With Torrent Pharma
Brief: Algorae Pharmaceuticals And Zydus Enter Exclusive Commercial Agreement
Brief: Algorae Pharmaceuticals Raises A$3.9 Million At A$0.012 Per Share
Brief: Algorae Pharmaceuticals Says TGA Accepts Initial Registration Dossier For Evaluation
Brief: Algorae Pharmaceuticals Partners With Peter Maccallum Cancer Centre For Second AI-Driven Drug Synergy Screening Program